Legis Daily

Neuromyelitis Optica Consortium Act

USA116th CongressHR-321| House 
| Updated: 1/25/2019
Barbara Lee

Barbara Lee

Democratic Representative

California

Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Neuromyelitis Optica Consortium Act This bill requires the National Institutes of Health to establish, administer, and coordinate a national consortium on neuromyelitis optica (NMO), which is a neurological disease that can cause blindness and paralysis. The consortium must award grants for research on the causes of, and the risk factors and biomarkers associated with, NMO; assemble a panel of experts to provide guidance and recommendations on research design and protocols; and designate a central laboratory to collect and analyze data from this research and to make the data and analysis available to researchers.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jan 8, 2019
Introduced in House
Jan 8, 2019
Referred to the House Committee on Energy and Commerce.
Jan 25, 2019
Referred to the Subcommittee on Health.
  • January 8, 2019
    Introduced in House


  • January 8, 2019
    Referred to the House Committee on Energy and Commerce.


  • January 25, 2019
    Referred to the Subcommittee on Health.

Health

Congressional oversightDepartment of Health and Human ServicesExecutive agency funding and structureHealth programs administration and fundingHearing, speech, and vision careMedical researchNational Institutes of Health (NIH)Neurological disordersResearch administration and funding

Neuromyelitis Optica Consortium Act

USA116th CongressHR-321| House 
| Updated: 1/25/2019
Neuromyelitis Optica Consortium Act This bill requires the National Institutes of Health to establish, administer, and coordinate a national consortium on neuromyelitis optica (NMO), which is a neurological disease that can cause blindness and paralysis. The consortium must award grants for research on the causes of, and the risk factors and biomarkers associated with, NMO; assemble a panel of experts to provide guidance and recommendations on research design and protocols; and designate a central laboratory to collect and analyze data from this research and to make the data and analysis available to researchers.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Jan 8, 2019
Introduced in House
Jan 8, 2019
Referred to the House Committee on Energy and Commerce.
Jan 25, 2019
Referred to the Subcommittee on Health.
  • January 8, 2019
    Introduced in House


  • January 8, 2019
    Referred to the House Committee on Energy and Commerce.


  • January 25, 2019
    Referred to the Subcommittee on Health.
Barbara Lee

Barbara Lee

Democratic Representative

California

Health Subcommittee, Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Congressional oversightDepartment of Health and Human ServicesExecutive agency funding and structureHealth programs administration and fundingHearing, speech, and vision careMedical researchNational Institutes of Health (NIH)Neurological disordersResearch administration and funding